

Appl. No. : 09/272,835  
Filed : March 19, 1999

Remarks

The specification has been amended to clarify discrepancies regarding the designation of SEQ ID Nos. 21 and 22. The amendments to the specification are of formal nature, and do not add new matter.

Sequence Rule Compliance

Along with the present Amendment, Applicants file a Sequence Listing in paper copy and computer readable form along with a statement that the two versions are the same, and do not add new matter to the specification. The entry of the Sequence Listing, which is in full compliance with the requirements of 37 C.F.R. § 1.821 through 1.825, is respectfully requested. A copy of the "Notice to Comply" is returned with the present Amendment. The specific issues raised by the Examiner are addressed as follows.

(1) The Examiner noted that under 37 CFR 1.821 (a)(2)(c-d) "each sequence disclosed must appear separately in the 'Sequence Listing' and in the text of the description and claims," and suggested that the present application does not comply with the requirement. The Applicants respectfully disagree and point out that the present application does comply with the requirement and that each sequence disclosed in the Sequence Listing is also disclosed in the text of the application. For the Examiner's convenience, sequence designations in the text are as follows:

SEQ ID NO	Location in Text
1	page 47, line 7
2	page 47, lines 7-8
3	page 47, line 8
4	page 47, lines 11-12
5	page 47, line 12
6	page 8, line 2
7	page 8, line 2
8	page 47, line 16
9	page 47, line 16

Appl. No. : 09/272,835  
Filed : March 19, 1999

10	page 48, lines 5-10
11	page 48, line 13
12	page 48, line 14
13	page 48, lines 33-34
14	page 49, lines 3-4
15	page 49, lines 4-5
16	page 49, line 4
17	page 49, line 9
18	page 54, line 3
19	page 55, line 34
20	page 56, line 17
21	page 49, lines 16-17
22	page 51, lines 21-22
23	page 51, line 22
24	page 51, lines 24
25	page 51, lines 24-25

(2) The Examiner noted that “it is also unclear what SEQ ID Nos: 18-20 represent.” The Applicants respectfully disagree and point out that SEQ ID No. 18 clearly represents GFR $\alpha$ 3-IgG as disclosed on page 54, line 36, SEQ ID No. 19 represents gD-GFR $\alpha$ 2-Rse-gD as disclosed on page 55, line 34, and SEQ ID NO. 20 represents gD-GFR $\alpha$ 3-Rse-gD as disclosed on page 56, line 15.

(3) The representation of SEQ ID Nos: 21-22 on page 7, line 36 was found by the Examiner to be inconsistent with the representation of SEQ ID Nos: 21-22 on pages 49 and 51. The representation of SEQ ID Nos: 21-22 on page 7, line 36 has been removed, leaving the appropriate representation of SEQ ID Nos: 21-22 on pages 49 and 51, respectively.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned “**Version with markings to show changes made.**”


Appl. No. : 89/272,835  
Filed : March 19, 1999

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: August 2, 2001

By:   
Ginger R. Dreger  
Registration No. 33,055  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660

Appl. No. : 09/272,835  
Filed : March 19, 1999

**Version with markings to show changes made**

**In the Specification:**

**In the Specification:**

Please replace the paragraph beginning at page 7, line 35, with the following rewritten paragraph:

--Figure 5A-B shows the nucleic acid sequence alignment of the DNA sequence (SEQ ID NO: 14) encoding human GFR $\alpha$ 3 with DNAs [(SEQ ID NO: 21 and SEQ ID NO: 22)] encoding human GFR $\alpha$ 1 (SEQ ID NO: 6) and human GFR $\alpha$ 2 (SEQ ID NO: 7), respectively.

W:\DOCS\BGY\BGY-1485.DOC  
072501